Adverse Events Report for NCT03421379 - JSON Representation - Evidence Based Medicine on FHIR Implementation Guide v1.0.0-ballot3

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0-ballot3 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
: Adverse Events Report for NCT03421379

Raw json | Download
{
  "resourceType" : "Composition",
  "id" : "399874",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2025-12-11T20:35:21.032Z",
    "profile" : [
      🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"
    ]
  },
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><p class=\"res-header-id\"><b>Generated Narrative: Composition 399874</b></p><a name=\"399874\"> </a><a name=\"hc399874\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">version: 5; Last updated: 2025-12-11 20:35:21+0000; Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-outcome-measure-report.html\">OutcomeMeasureReport</a></p></div><p><b>url</b>: <a href=\"https://fevir.net/resources/Composition/399874\">https://fevir.net/resources/Composition/399874</a></p><p><b>identifier</b>: FEvIR Object Identifier/399874, FEvIR Linking Identifier/NCT03421379-adverse-events-report</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://fevir.net/resources/CodeSystem/179423 OutcomeMeasureReport}\">Outcome Measure Report</span></p><p><b>date</b>: 2025-12-11 20:35:21+0000</p><p><b>author</b>: [No author listed.]</p><p><b>title</b>: Adverse Events Report for NCT03421379</p><p><b>custodian</b>: <a href=\"Organization-118079.html\">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Type</b></td><td><b>Target[x]</b></td></tr><tr><td style=\"display: none\">*</td><td>Cite As</td><td><div><p>Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json.</p>\n</div></td></tr></table><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-AllCauseMortality</b></p><a name=\"399874/NCT03421379-AllCauseMortality\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: All-cause mortality (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">All-cause mortality</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-SeriousAdverseEvents</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Serious Adverse Events (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Serious Adverse Events</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvents</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Other Adverse Events (timeframe for NCT03421379)</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Other Adverse Events</span></td></tr></table><p><b>handling</b>: boolean variable</p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-AllCauseMortality-EG000</b></p><a name=\"399874/NCT03421379-AllCauseMortality-EG000\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_AllCauseMortality_EG000</p><p><b>title</b>: All-cause mortality for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-AllCauseMortality\">EvidenceVariable All-cause mortality (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvents-EG000</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents-EG000\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvents_EG000</p><p><b>title</b>: Serious Adverse Events for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvents\">EvidenceVariable Serious Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvents-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvents_EG000</p><p><b>title</b>: Other Adverse Events for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvents\">EvidenceVariable Other Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.2113</p><p><b>numberAffected</b>: 15</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-AllCauseMortality-EG001</b></p><a name=\"399874/NCT03421379-AllCauseMortality-EG001\"> </a><a name=\"hc399874/NCT03421379-AllCauseMortality-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_AllCauseMortality_EG001</p><p><b>title</b>: All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-AllCauseMortality\">EvidenceVariable All-cause mortality (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvents-EG001</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvents-EG001\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvents-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvents_EG001</p><p><b>title</b>: Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvents\">EvidenceVariable Serious Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvents-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvents-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvents-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvents_EG001</p><p><b>title</b>: Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvents\">EvidenceVariable Other Adverse Events (timeframe for NCT03421379)</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.1857</p><p><b>numberAffected</b>: 13</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvent-0-EG000</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0-EG000\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvent_0_EG000</p><p><b>title</b>: Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvent-0\">EvidenceVariable Vertigo positional as serious adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-SeriousAdverseEvent-0-EG001</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0-EG001\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_SeriousAdverseEvent_0_EG001</p><p><b>title</b>: Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-SeriousAdverseEvent-0\">EvidenceVariable Vertigo positional as serious adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-SeriousAdverseEvent-0</b></p><a name=\"399874/NCT03421379-SeriousAdverseEvent-0\"> </a><a name=\"hc399874/NCT03421379-SeriousAdverseEvent-0\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Vertigo positional as serious adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Vertigo positional as serious adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Serious Adverse Event</span>, <span title=\"Codes:\">Ear and labyrinth disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-0-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_0_EG000</p><p><b>title</b>: Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-0\">EvidenceVariable Ear pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0282</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-0-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_0_EG001</p><p><b>title</b>: Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-0\">EvidenceVariable Ear pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-0</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-0\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-0\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Ear pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Ear pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Ear and labyrinth disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-1-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_1_EG000</p><p><b>title</b>: Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-1\">EvidenceVariable Eye pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-1-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_1_EG001</p><p><b>title</b>: Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-1\">EvidenceVariable Eye pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-1</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-1\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-1\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Eye pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Eye pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-2-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_2_EG000</p><p><b>title</b>: Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-2\">EvidenceVariable Eye pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-2-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_2_EG001</p><p><b>title</b>: Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-2\">EvidenceVariable Eye pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-2</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-2\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-2\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Eye pruritus as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Eye pruritus as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-3-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_3_EG000</p><p><b>title</b>: Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-3\">EvidenceVariable Lacrimation increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-3-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_3_EG001</p><p><b>title</b>: Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-3\">EvidenceVariable Lacrimation increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-3</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-3\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-3\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Lacrimation increased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Lacrimation increased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Eye disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-4-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_4_EG000</p><p><b>title</b>: Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-4\">EvidenceVariable Diarrhoea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-4-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_4_EG001</p><p><b>title</b>: Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-4\">EvidenceVariable Diarrhoea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-4</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-4\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-4\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Diarrhoea as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Diarrhoea as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-5-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_5_EG000</p><p><b>title</b>: Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-5\">EvidenceVariable Nausea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0704</p><p><b>numberOfEvents</b>: 5</p><p><b>numberAffected</b>: 5</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-5-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_5_EG001</p><p><b>title</b>: Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-5\">EvidenceVariable Nausea as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.1571</p><p><b>numberOfEvents</b>: 11</p><p><b>numberAffected</b>: 11</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-5</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-5\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-5\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nausea as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nausea as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-6-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_6_EG000</p><p><b>title</b>: Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-6\">EvidenceVariable Toothache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-6-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_6_EG001</p><p><b>title</b>: Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-6\">EvidenceVariable Toothache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-6</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-6\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-6\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Toothache as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Toothache as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-7-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_7_EG000</p><p><b>title</b>: Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-7\">EvidenceVariable Vomiting as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0282</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-7-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_7_EG001</p><p><b>title</b>: Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-7\">EvidenceVariable Vomiting as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0571</p><p><b>numberOfEvents</b>: 5</p><p><b>numberAffected</b>: 4</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-7</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-7\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-7\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Vomiting as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Vomiting as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Gastrointestinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-8-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_8_EG000</p><p><b>title</b>: Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-8\">EvidenceVariable Feeling abnormal as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-8-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_8_EG001</p><p><b>title</b>: Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-8\">EvidenceVariable Feeling abnormal as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-8</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-8\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-8\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Feeling abnormal as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Feeling abnormal as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">General disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-9-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_9_EG000</p><p><b>title</b>: Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-9\">EvidenceVariable Cystitis as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-9-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_9_EG001</p><p><b>title</b>: Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-9\">EvidenceVariable Cystitis as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-9</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-9\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-9\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Cystitis as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Cystitis as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Infections and infestations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-10-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_10_EG000</p><p><b>title</b>: Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-10\">EvidenceVariable Blood pressure decreased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-10-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_10_EG001</p><p><b>title</b>: Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-10\">EvidenceVariable Blood pressure decreased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0286</p><p><b>numberOfEvents</b>: 2</p><p><b>numberAffected</b>: 2</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-10</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-10\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-10\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Blood pressure decreased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Blood pressure decreased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Investigations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-11-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_11_EG000</p><p><b>title</b>: Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-11\">EvidenceVariable Blood pressure increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0563</p><p><b>numberOfEvents</b>: 4</p><p><b>numberAffected</b>: 4</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-11-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_11_EG001</p><p><b>title</b>: Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-11\">EvidenceVariable Blood pressure increased as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-11</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-11\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-11\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Blood pressure increased as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Blood pressure increased as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Investigations</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-12-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_12_EG000</p><p><b>title</b>: Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-12\">EvidenceVariable Back pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-12-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_12_EG001</p><p><b>title</b>: Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-12\">EvidenceVariable Back pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-12</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-12\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-12\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Back pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Back pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Musculoskeletal and connective tissue disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-13-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_13_EG000</p><p><b>title</b>: Headache as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-13\">EvidenceVariable Headache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-13-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_13_EG001</p><p><b>title</b>: Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-13\">EvidenceVariable Headache as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-13</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-13\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-13\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Headache as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Headache as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Nervous system disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-14-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_14_EG000</p><p><b>title</b>: Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-14\">EvidenceVariable Nasal congestion as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-14-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_14_EG001</p><p><b>title</b>: Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-14\">EvidenceVariable Nasal congestion as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-14</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-14\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-14\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nasal congestion as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nasal congestion as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-15-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_15_EG000</p><p><b>title</b>: Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-15\">EvidenceVariable Nasal pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-15-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_15_EG001</p><p><b>title</b>: Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-15\">EvidenceVariable Nasal pruritus as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-15</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-15\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-15\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Nasal pruritus as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Nasal pruritus as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-16-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_16_EG000</p><p><b>title</b>: Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-16\">EvidenceVariable Oropharyngeal pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0141</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-16-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_16_EG001</p><p><b>title</b>: Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-16\">EvidenceVariable Oropharyngeal pain as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-16</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-16\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-16\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Oropharyngeal pain as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Oropharyngeal pain as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-17-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_17_EG000</p><p><b>title</b>: Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-17\">EvidenceVariable Rhinalgia as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0845</p><p><b>numberOfEvents</b>: 6</p><p><b>numberAffected</b>: 6</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-17-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_17_EG001</p><p><b>title</b>: Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-17\">EvidenceVariable Rhinalgia as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-17</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-17\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-17\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Rhinalgia as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Rhinalgia as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Respiratory, thoracic and mediastinal disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-18-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_18_EG000</p><p><b>title</b>: Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-18\">EvidenceVariable Cold sweat as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-18-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_18_EG001</p><p><b>title</b>: Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-18\">EvidenceVariable Cold sweat as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-18</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-18\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-18\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Cold sweat as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Cold sweat as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Skin and subcutaneous tissue disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-19-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_19_EG000</p><p><b>title</b>: Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-19\">EvidenceVariable Hot flush as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-19-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_19_EG001</p><p><b>title</b>: Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-19\">EvidenceVariable Hot flush as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-19</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-19\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-19\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Hot flush as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Hot flush as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-20-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_20_EG000</p><p><b>title</b>: Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-20\">EvidenceVariable Hypertension as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-20-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_20_EG001</p><p><b>title</b>: Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-20\">EvidenceVariable Hypertension as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-20</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-20\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-20\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Hypertension as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Hypertension as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-21-EG000</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21-EG000\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21-EG000\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_21_EG000</p><p><b>title</b>: Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Nasal Powder</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 3 mg glucagon nasal powder was administered intranasally</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-21\">EvidenceVariable Peripheral coldness as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0</p><p><b>numberOfEvents</b>: 0</p><p><b>numberAffected</b>: 0</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>71</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: Evidence #NCT03421379-OtherAdverseEvent-21-EG001</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21-EG001\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21-EG001\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-non-comparative-evidence.html\">NonComparativeEvidence</a></p></div><p><b>name</b>: NCT03421379_OtherAdverseEvent_21_EG001</p><p><b>title</b>: Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379</p><p><b>status</b>: Active</p><blockquote><p><b>variableDefinition</b></p><p><b>description</b>: </p><div><p>Glucagon Hydrochloride Solution</p>\n</div><p><b>variableRole</b>: Population</p><p><b>observed</b>: A single dose of 1 mg glucagon hydrochloride solution was administered IM</p></blockquote><blockquote><p><b>variableDefinition</b></p><p><b>note</b>: </p><blockquote><div><p>All randomized participants who received at least one dose of study drug.</p>\n</div></blockquote><p><b>variableRole</b>: Outcome</p><p><b>observed</b>: <a href=\"#hc399874/NCT03421379-OtherAdverseEvent-21\">EvidenceVariable Peripheral coldness as other adverse event</a></p></blockquote><blockquote><p><b>statistic</b></p><p><b>statisticType</b>: <span title=\"Codes:\">Percentage</span></p><p><b>quantity</b>: 0.0143</p><p><b>numberOfEvents</b>: 1</p><p><b>numberAffected</b>: 1</p><h3>SampleSizes</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>KnownDataCount</b></td></tr><tr><td style=\"display: none\">*</td><td>70</td></tr></table></blockquote></blockquote><hr/><blockquote><p class=\"res-header-id\"><b>Generated Narrative: EvidenceVariable #NCT03421379-OtherAdverseEvent-21</b></p><a name=\"399874/NCT03421379-OtherAdverseEvent-21\"> </a><a name=\"hc399874/NCT03421379-OtherAdverseEvent-21\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\"/><p style=\"margin-bottom: 0px\">Profile: <a href=\"StructureDefinition-variable-definition.html\">VariableDefinition</a></p></div><p><b>title</b>: Peripheral coldness as other adverse event</p><p><b>status</b>: Active</p><h3>Definitions</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Concept</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:\">Peripheral coldness as other adverse event</span></td></tr></table><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Adverse event assessment type</span></p><p><b>value</b>: <span title=\"Codes:{http://hl7.org/fhir/definition-method systematic-assessment}\">Systematic Assessment</span></p></blockquote><blockquote><p><b>definitionModifier</b></p><p><b>code</b>: <span title=\"Codes:\">Source Vocabulary for Adverse Event Definition</span></p><p><b>value</b>: <span title=\"Codes:\">MedDRA 18.1</span></p></blockquote><p><b>handling</b>: boolean variable</p><p><b>classifier</b>: <span title=\"Codes:\">Other Adverse Event</span>, <span title=\"Codes:\">Vascular disorders</span></p><h3>Timings</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Text</b></td></tr><tr><td style=\"display: none\">*</td><td>From Baseline to End of Follow-up (Up to 2 Months)</td></tr></table></blockquote></div>"
  },
  "contained" : [
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-AllCauseMortality",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "All-cause mortality (timeframe for NCT03421379)",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "All-cause mortality"
        }
      },
      "handling" : "boolean",
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-SeriousAdverseEvents",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Serious Adverse Events (timeframe for NCT03421379)",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Serious Adverse Events"
        }
      },
      "handling" : "boolean",
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvents",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Other Adverse Events (timeframe for NCT03421379)",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Other Adverse Events"
        }
      },
      "handling" : "boolean",
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-AllCauseMortality-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_AllCauseMortality_EG000",
      "title" : "All-cause mortality for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-AllCauseMortality",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-SeriousAdverseEvents-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_SeriousAdverseEvents_EG000",
      "title" : "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-SeriousAdverseEvents",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvents-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvents_EG000",
      "title" : "Other Adverse Events for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvents",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.2113
          },
          "numberAffected" : 15,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-AllCauseMortality-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_AllCauseMortality_EG001",
      "title" : "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-AllCauseMortality",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-SeriousAdverseEvents-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_SeriousAdverseEvents_EG001",
      "title" : "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-SeriousAdverseEvents",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvents-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvents_EG001",
      "title" : "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvents",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.1857
          },
          "numberAffected" : 13,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-SeriousAdverseEvent-0-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_SeriousAdverseEvent_0_EG000",
      "title" : "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-SeriousAdverseEvent-0",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-SeriousAdverseEvent-0-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_SeriousAdverseEvent_0_EG001",
      "title" : "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-SeriousAdverseEvent-0",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-SeriousAdverseEvent-0",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Vertigo positional as serious adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Vertigo positional as serious adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Serious Adverse Event"
        },
        {
          "text" : "Ear and labyrinth disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-0-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_0_EG000",
      "title" : "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-0",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0282
          },
          "numberOfEvents" : 2,
          "numberAffected" : 2,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-0-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_0_EG001",
      "title" : "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-0",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-0",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Ear pain as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Ear pain as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Ear and labyrinth disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-1-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_1_EG000",
      "title" : "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-1",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-1-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_1_EG001",
      "title" : "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-1",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-1",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Eye pain as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Eye pain as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Eye disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-2-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_2_EG000",
      "title" : "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-2",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-2-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_2_EG001",
      "title" : "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-2",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-2",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Eye pruritus as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Eye pruritus as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Eye disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-3-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_3_EG000",
      "title" : "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-3",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-3-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_3_EG001",
      "title" : "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-3",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-3",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Lacrimation increased as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Lacrimation increased as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Eye disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-4-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_4_EG000",
      "title" : "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-4",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-4-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_4_EG001",
      "title" : "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-4",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-4",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Diarrhoea as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Diarrhoea as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Gastrointestinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-5-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_5_EG000",
      "title" : "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-5",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0704
          },
          "numberOfEvents" : 5,
          "numberAffected" : 5,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-5-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_5_EG001",
      "title" : "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-5",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.1571
          },
          "numberOfEvents" : 11,
          "numberAffected" : 11,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-5",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Nausea as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Nausea as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Gastrointestinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-6-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_6_EG000",
      "title" : "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-6",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-6-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_6_EG001",
      "title" : "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-6",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-6",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Toothache as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Toothache as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Gastrointestinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-7-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_7_EG000",
      "title" : "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-7",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0282
          },
          "numberOfEvents" : 2,
          "numberAffected" : 2,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-7-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_7_EG001",
      "title" : "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-7",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0571
          },
          "numberOfEvents" : 5,
          "numberAffected" : 4,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-7",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Vomiting as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Vomiting as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Gastrointestinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-8-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_8_EG000",
      "title" : "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-8",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-8-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_8_EG001",
      "title" : "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-8",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-8",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Feeling abnormal as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Feeling abnormal as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "General disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-9-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_9_EG000",
      "title" : "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-9",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-9-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_9_EG001",
      "title" : "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-9",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-9",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Cystitis as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Cystitis as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Infections and infestations"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-10-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_10_EG000",
      "title" : "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-10",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-10-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_10_EG001",
      "title" : "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-10",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0286
          },
          "numberOfEvents" : 2,
          "numberAffected" : 2,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-10",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Blood pressure decreased as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Blood pressure decreased as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Investigations"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-11-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_11_EG000",
      "title" : "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-11",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0563
          },
          "numberOfEvents" : 4,
          "numberAffected" : 4,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-11-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_11_EG001",
      "title" : "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-11",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-11",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Blood pressure increased as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Blood pressure increased as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Investigations"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-12-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_12_EG000",
      "title" : "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-12",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-12-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_12_EG001",
      "title" : "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-12",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-12",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Back pain as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Back pain as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Musculoskeletal and connective tissue disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-13-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_13_EG000",
      "title" : "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-13",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-13-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_13_EG001",
      "title" : "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-13",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-13",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Headache as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Headache as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Nervous system disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-14-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_14_EG000",
      "title" : "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-14",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-14-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_14_EG001",
      "title" : "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-14",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-14",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Nasal congestion as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Nasal congestion as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-15-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_15_EG000",
      "title" : "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-15",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-15-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_15_EG001",
      "title" : "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-15",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-15",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Nasal pruritus as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Nasal pruritus as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-16-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_16_EG000",
      "title" : "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-16",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0141
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-16-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_16_EG001",
      "title" : "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-16",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-16",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Oropharyngeal pain as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Oropharyngeal pain as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-17-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_17_EG000",
      "title" : "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-17",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0845
          },
          "numberOfEvents" : 6,
          "numberAffected" : 6,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-17-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_17_EG001",
      "title" : "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-17",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-17",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Rhinalgia as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Rhinalgia as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Respiratory, thoracic and mediastinal disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-18-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_18_EG000",
      "title" : "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-18",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-18-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_18_EG001",
      "title" : "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-18",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-18",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Cold sweat as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Cold sweat as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Skin and subcutaneous tissue disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-19-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_19_EG000",
      "title" : "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-19",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-19-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_19_EG001",
      "title" : "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-19",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-19",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Hot flush as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Hot flush as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Vascular disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-20-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_20_EG000",
      "title" : "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-20",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-20-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_20_EG001",
      "title" : "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-20",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-20",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Hypertension as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Hypertension as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Vascular disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-21-EG000",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_21_EG000",
      "title" : "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Nasal Powder",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 3 mg glucagon nasal powder was administered intranasally"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-21",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0
          },
          "numberOfEvents" : 0,
          "numberAffected" : 0,
          "sampleSize" : {
            "knownDataCount" : 71
          }
        }
      ]
    },
    {
      "resourceType" : "Evidence",
      "id" : "NCT03421379-OtherAdverseEvent-21-EG001",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/non-comparative-evidence"
        ]
      },
      "name" : "NCT03421379_OtherAdverseEvent_21_EG001",
      "title" : "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379",
      "status" : "active",
      "variableDefinition" : [
        {
          "description" : "Glucagon Hydrochloride Solution",
          "variableRole" : "population",
          "observed" : {
            "display" : "A single dose of 1 mg glucagon hydrochloride solution was administered IM"
          }
        },
        {
          "note" : [
            {
              "text" : "All randomized participants who received at least one dose of study drug."
            }
          ],
          "variableRole" : "outcome",
          "observed" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-21",
            "type" : "EvidenceVariable"
          }
        }
      ],
      "statistic" : [
        {
          "statisticType" : {
            "text" : "Percentage"
          },
          "quantity" : {
            "value" : 0.0143
          },
          "numberOfEvents" : 1,
          "numberAffected" : 1,
          "sampleSize" : {
            "knownDataCount" : 70
          }
        }
      ]
    },
    {
      "resourceType" : "EvidenceVariable",
      "id" : "NCT03421379-OtherAdverseEvent-21",
      "meta" : {
        "profile" : [
          🔗 "http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"
        ]
      },
      "title" : "Peripheral coldness as other adverse event",
      "status" : "active",
      "definition" : {
        "concept" : {
          "text" : "Peripheral coldness as other adverse event"
        }
      },
      "definitionModifier" : [
        {
          "code" : {
            "text" : "Adverse event assessment type"
          },
          "valueCodeableConcept" : {
            "coding" : [
              {
                "system" : "http://hl7.org/fhir/definition-method",
                "code" : "systematic-assessment",
                "display" : "Systematic Assessment"
              }
            ]
          }
        },
        {
          "code" : {
            "text" : "Source Vocabulary for Adverse Event Definition"
          },
          "valueCodeableConcept" : {
            "text" : "MedDRA 18.1"
          }
        }
      ],
      "handling" : "boolean",
      "classifier" : [
        {
          "text" : "Other Adverse Event"
        },
        {
          "text" : "Vascular disorders"
        }
      ],
      "timing" : {
        "text" : "From Baseline to End of Follow-up (Up to 2 Months)"
      }
    }
  ],
  "url" : "https://fevir.net/resources/Composition/399874",
  "identifier" : [
    {
      "type" : {
        "coding" : [
          {
            "system" : "http://terminology.hl7.org/CodeSystem/v2-0203",
            "code" : "ACSN",
            "display" : "Accession ID"
          }
        ],
        "text" : "FEvIR Object Identifier"
      },
      "system" : "https://fevir.net/FOI",
      "value" : "399874",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    },
    {
      "type" : {
        "text" : "FEvIR Linking Identifier"
      },
      "system" : "https://fevir.net/FLI",
      "value" : "NCT03421379-adverse-events-report",
      "assigner" : {
        "display" : "Computable Publishing LLC"
      }
    }
  ],
  "status" : "final",
  "type" : {
    "coding" : [
      {
        "system" : "https://fevir.net/resources/CodeSystem/179423",
        "code" : "OutcomeMeasureReport",
        "display" : "OutcomeMeasureReport"
      }
    ],
    "text" : "Outcome Measure Report"
  },
  "date" : "2025-12-11T20:35:21.032Z",
  "author" : [
    {
      "display" : "[No author listed.]"
    }
  ],
  "title" : "Adverse Events Report for NCT03421379",
  "custodian" : {
    🔗 "reference" : "Organization/118079",
    "type" : "Organization",
    "display" : "Computable Publishing LLC"
  },
  "relatesTo" : [
    {
      "type" : "cite-as",
      "targetMarkdown" : "Adverse Events Report for NCT03421379 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 399874. Revised 2025-12-11. Available at: https://fevir.net/resources/Composition/399874. Computable resource at: https://fevir.net/resources/Composition/399874#json."
    }
  ],
  "section" : [
    {
      "title" : "Events Frequency Threshold",
      "code" : {
        "text" : "EventsFrequencyThreshold"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">0%</div>"
      }
    },
    {
      "title" : "Events Time Frame",
      "code" : {
        "text" : "EventsTimeFrame"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">From Baseline to End of Follow-up (Up to 2 Months)</div>"
      }
    },
    {
      "title" : "Events Description",
      "code" : {
        "text" : "EventsDescription"
      },
      "text" : {
        "status" : "generated",
        "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants who received at least one dose of study drug.</div>"
      }
    },
    {
      "title" : "Glucagon Nasal Powder",
      "code" : {
        "text" : "EG000 Glucagon Nasal Powder"
      },
      "section" : [
        {
          "title" : "Event Group Description",
          "code" : {
            "text" : "EventGroupDescription"
          },
          "text" : {
            "status" : "generated",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 3 mg glucagon nasal powder was administered intranasally</div>"
          }
        }
      ]
    },
    {
      "title" : "Glucagon Hydrochloride Solution",
      "code" : {
        "text" : "EG001 Glucagon Hydrochloride Solution"
      },
      "section" : [
        {
          "title" : "Event Group Description",
          "code" : {
            "text" : "EventGroupDescription"
          },
          "text" : {
            "status" : "generated",
            "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">A single dose of 1 mg glucagon hydrochloride solution was administered IM</div>"
          }
        }
      ]
    },
    {
      "title" : "Total Mortality",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Total Mortality"
      },
      "focus" : {
        "reference" : "#NCT03421379-AllCauseMortality",
        "type" : "EvidenceVariable",
        "display" : "All-cause mortality (timeframe for NCT03421379)"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-AllCauseMortality-EG000",
          "type" : "Evidence",
          "display" : "All-cause mortality for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "#NCT03421379-AllCauseMortality-EG001",
          "type" : "Evidence",
          "display" : "All-cause mortality for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title" : "Total Serious Events",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Total Serious Events"
      },
      "focus" : {
        "reference" : "#NCT03421379-SeriousAdverseEvents",
        "type" : "EvidenceVariable",
        "display" : "Serious Adverse Events (timeframe for NCT03421379)"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-SeriousAdverseEvents-EG000",
          "type" : "Evidence",
          "display" : "Serious Adverse Events for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "#NCT03421379-SeriousAdverseEvents-EG001",
          "type" : "Evidence",
          "display" : "Serious Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title" : "Total Other Events",
      "code" : {
        "coding" : [
          {
            "system" : "https://fevir.net/resources/CodeSystem/179423",
            "code" : "results",
            "display" : "Results"
          }
        ],
        "text" : "Total Other Events"
      },
      "focus" : {
        "reference" : "#NCT03421379-OtherAdverseEvents",
        "type" : "EvidenceVariable",
        "display" : "Other Adverse Events (timeframe for NCT03421379)"
      },
      "entry" : [
        {
          "reference" : "#NCT03421379-OtherAdverseEvents-EG000",
          "type" : "Evidence",
          "display" : "Other Adverse Events for Glucagon Nasal Powder in NCT03421379"
        },
        {
          "reference" : "#NCT03421379-OtherAdverseEvents-EG001",
          "type" : "Evidence",
          "display" : "Other Adverse Events for Glucagon Hydrochloride Solution in NCT03421379"
        }
      ]
    },
    {
      "title" : "Serious Event List",
      "code" : {
        "text" : "SeriousEventList"
      },
      "section" : [
        {
          "title" : "Vertigo positional",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-SeriousAdverseEvent-0",
            "type" : "EvidenceVariable",
            "display" : "Vertigo positional as serious adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-SeriousAdverseEvent-0-EG000",
              "type" : "Evidence",
              "display" : "Vertigo positional as serious adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-SeriousAdverseEvent-0-EG001",
              "type" : "Evidence",
              "display" : "Vertigo positional as serious adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        }
      ]
    },
    {
      "title" : "Other Event List",
      "code" : {
        "text" : "OtherEventList"
      },
      "section" : [
        {
          "title" : "Ear pain",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-0",
            "type" : "EvidenceVariable",
            "display" : "Ear pain as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-0-EG000",
              "type" : "Evidence",
              "display" : "Ear pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-0-EG001",
              "type" : "Evidence",
              "display" : "Ear pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Eye pain",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-1",
            "type" : "EvidenceVariable",
            "display" : "Eye pain as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-1-EG000",
              "type" : "Evidence",
              "display" : "Eye pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-1-EG001",
              "type" : "Evidence",
              "display" : "Eye pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Eye pruritus",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-2",
            "type" : "EvidenceVariable",
            "display" : "Eye pruritus as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-2-EG000",
              "type" : "Evidence",
              "display" : "Eye pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-2-EG001",
              "type" : "Evidence",
              "display" : "Eye pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Lacrimation increased",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-3",
            "type" : "EvidenceVariable",
            "display" : "Lacrimation increased as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-3-EG000",
              "type" : "Evidence",
              "display" : "Lacrimation increased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-3-EG001",
              "type" : "Evidence",
              "display" : "Lacrimation increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Diarrhoea",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-4",
            "type" : "EvidenceVariable",
            "display" : "Diarrhoea as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-4-EG000",
              "type" : "Evidence",
              "display" : "Diarrhoea as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-4-EG001",
              "type" : "Evidence",
              "display" : "Diarrhoea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Nausea",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-5",
            "type" : "EvidenceVariable",
            "display" : "Nausea as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-5-EG000",
              "type" : "Evidence",
              "display" : "Nausea as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-5-EG001",
              "type" : "Evidence",
              "display" : "Nausea as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Toothache",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-6",
            "type" : "EvidenceVariable",
            "display" : "Toothache as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-6-EG000",
              "type" : "Evidence",
              "display" : "Toothache as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-6-EG001",
              "type" : "Evidence",
              "display" : "Toothache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Vomiting",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-7",
            "type" : "EvidenceVariable",
            "display" : "Vomiting as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-7-EG000",
              "type" : "Evidence",
              "display" : "Vomiting as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-7-EG001",
              "type" : "Evidence",
              "display" : "Vomiting as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Feeling abnormal",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-8",
            "type" : "EvidenceVariable",
            "display" : "Feeling abnormal as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-8-EG000",
              "type" : "Evidence",
              "display" : "Feeling abnormal as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-8-EG001",
              "type" : "Evidence",
              "display" : "Feeling abnormal as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Cystitis",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-9",
            "type" : "EvidenceVariable",
            "display" : "Cystitis as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-9-EG000",
              "type" : "Evidence",
              "display" : "Cystitis as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-9-EG001",
              "type" : "Evidence",
              "display" : "Cystitis as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Blood pressure decreased",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-10",
            "type" : "EvidenceVariable",
            "display" : "Blood pressure decreased as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-10-EG000",
              "type" : "Evidence",
              "display" : "Blood pressure decreased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-10-EG001",
              "type" : "Evidence",
              "display" : "Blood pressure decreased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Blood pressure increased",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-11",
            "type" : "EvidenceVariable",
            "display" : "Blood pressure increased as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-11-EG000",
              "type" : "Evidence",
              "display" : "Blood pressure increased as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-11-EG001",
              "type" : "Evidence",
              "display" : "Blood pressure increased as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Back pain",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-12",
            "type" : "EvidenceVariable",
            "display" : "Back pain as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-12-EG000",
              "type" : "Evidence",
              "display" : "Back pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-12-EG001",
              "type" : "Evidence",
              "display" : "Back pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Headache",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-13",
            "type" : "EvidenceVariable",
            "display" : "Headache as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-13-EG000",
              "type" : "Evidence",
              "display" : "Headache as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-13-EG001",
              "type" : "Evidence",
              "display" : "Headache as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Nasal congestion",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-14",
            "type" : "EvidenceVariable",
            "display" : "Nasal congestion as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-14-EG000",
              "type" : "Evidence",
              "display" : "Nasal congestion as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-14-EG001",
              "type" : "Evidence",
              "display" : "Nasal congestion as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Nasal pruritus",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-15",
            "type" : "EvidenceVariable",
            "display" : "Nasal pruritus as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-15-EG000",
              "type" : "Evidence",
              "display" : "Nasal pruritus as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-15-EG001",
              "type" : "Evidence",
              "display" : "Nasal pruritus as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Oropharyngeal pain",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-16",
            "type" : "EvidenceVariable",
            "display" : "Oropharyngeal pain as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-16-EG000",
              "type" : "Evidence",
              "display" : "Oropharyngeal pain as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-16-EG001",
              "type" : "Evidence",
              "display" : "Oropharyngeal pain as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Rhinalgia",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-17",
            "type" : "EvidenceVariable",
            "display" : "Rhinalgia as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-17-EG000",
              "type" : "Evidence",
              "display" : "Rhinalgia as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-17-EG001",
              "type" : "Evidence",
              "display" : "Rhinalgia as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Cold sweat",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-18",
            "type" : "EvidenceVariable",
            "display" : "Cold sweat as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-18-EG000",
              "type" : "Evidence",
              "display" : "Cold sweat as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-18-EG001",
              "type" : "Evidence",
              "display" : "Cold sweat as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Hot flush",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-19",
            "type" : "EvidenceVariable",
            "display" : "Hot flush as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-19-EG000",
              "type" : "Evidence",
              "display" : "Hot flush as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-19-EG001",
              "type" : "Evidence",
              "display" : "Hot flush as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Hypertension",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-20",
            "type" : "EvidenceVariable",
            "display" : "Hypertension as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-20-EG000",
              "type" : "Evidence",
              "display" : "Hypertension as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-20-EG001",
              "type" : "Evidence",
              "display" : "Hypertension as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        },
        {
          "title" : "Peripheral coldness",
          "code" : {
            "coding" : [
              {
                "system" : "https://fevir.net/resources/CodeSystem/179423",
                "code" : "results",
                "display" : "Results"
              }
            ]
          },
          "focus" : {
            "reference" : "#NCT03421379-OtherAdverseEvent-21",
            "type" : "EvidenceVariable",
            "display" : "Peripheral coldness as other adverse event"
          },
          "entry" : [
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-21-EG000",
              "type" : "Evidence",
              "display" : "Peripheral coldness as other adverse event for Glucagon Nasal Powder in NCT03421379"
            },
            {
              "reference" : "#NCT03421379-OtherAdverseEvent-21-EG001",
              "type" : "Evidence",
              "display" : "Peripheral coldness as other adverse event for Glucagon Hydrochloride Solution in NCT03421379"
            }
          ]
        }
      ]
    }
  ]
}